Indeed, recently the rs4646 CYP19A1 polymorphism has been associated with letrozole efficacy in advance disease [29]; however, no evidence between CYP19A1 polymorphisms and therapeutic efficacy of aromatase inhibitors in early stage BC has yet been established. Here, CYP19A1 is linked to breast cancer.